Joe is the Founder of NanoSyrinx, along with Nick and Alexia and currently serves as the CEO of the company, having led the push to commercialise the technology during his PhD studies. He is passionate about biology, particularly bioinformatics and synthetic biology, and is keen to realise the potential of the technology, especially applied to NanoSyrinx’s unusual IP.

He holds a PhD and MSc in Mathematical Biology and Biophysical Chemistry from the University of Warwick, and graduated top of his class from his BSc (Hons) Biology degree.

Marie is a senior R&D leader with more than 20 years of drug discovery experience in the biotechnology industry and large pharma. She joined the company from GSK, where she was Senior Director in the Oncology Cell Therapy Research Unit. Marie has extensive knowledge of drug discovery across biopharms, cell and gene therapies and vaccines with a particular interest in the inter-relationships between safety, efficacy and manufacture. Throughout her career she has been accountable for delivering, reviewing and approving non-clinical safety and pharmacology packages to support non-regulatory project decisions and regulatory submissions.

Marie holds a Ph.D. in Rheumatology and Immunology from University of Birmingham, UK.

Edwin is a renowned entrepreneur and C-level executive in the life sciences industry, bringing over 30 years of Board-level experience from over 20 life science companies. Currently Chairman of NanoSyrinx Ltd, Achilles Therapeutics plc, LabGenius Ltd and Avantium NV, he has an impressive track record building and scaling innovative biotech platform companies, achieving multiple successful exits and raising over €700 million in equity and debt financing to date.

Previously, Edwin was CEO of Ablynx NV until its agreed takeover by Sanofi for $4.8 billion in 2018, and CEO of Oxford Asymmetry International plc prior to its sale to Evotec for £316 million. He led both companies’ successful IPOs on the London Stock Exchange, EuroNext and NASDAQ.

A highly experienced CBO, Jane brings a wealth of knowledge about business development and driving company growth, particularly for platform biotech companies. She serves on the boards of Spirea, PharmEnable, Macomics and is the Chair of the Sir Richard Stapley Educational Trust. With over 30 years in biotech and pharma business development, her past roles include Chief Business Officer at F-star, Vice President of Business Development at Cellzome, and Director of Business Development at MedImmune (formerly Cambridge Antibody Technologies).

Jane holds an MA and PhD in Natural Sciences from Cambridge University, as well as an MBA from the Cambridge Judge Business School.

Oliver sits in the Octopus Ventures bio team, where he’s excited to work with entrepreneurs changing people’s lives in healthcare and beyond.

He joins Octopus Ventures from a role in the family office of Jonathan Milner (Founder CEO of Abcam) one of the UK’s most successful biotech entrepreneurs, where he supported and backed early-stage companies working in the bioscience space.

Oliver’s professional experience is underpinned by a background in biomedical science and biochemistry, coupled with commercial execution of complex biotechnologies and business models. He’s worked in biologics drug discovery, gene editing tools, breath diagnostics, and digital prediction and mitigation tools for bipolar patients.

Lucy is an investor at BGF, the most active equity investor in the UK and Ireland with a balance sheet of £2.5bn. Lucy focuses on investments in the life sciences space, with a particular interest in drug discovery platforms. Her main role is to source and execute new investments, as well as supporting a number of investee companies at board level (currently Dunad Therapeutics, Maxion Therapeutics, ViaNautis Bio, Elasmogen, Enhanc3d Genomics).

Prior to BGF, Lucy spent five years in strategy consulting at CIL where she focused on the healthcare and pharma sectors.  Lucy holds a first-class degree in History from Durham University and a Master’s degree in Russian & Eastern European Studies from Oxford University.

Bauke joined M Ventures in 2019 and is currently a Principal in the Biotechnology team. Bauke is a board director or observer on NanoSyrinx, Pictor Labs, Synaffix, Immunitas Therapeutics and iOnctura. Before joining M Ventures, he was with Jefferies International in the Healthcare Investment Banking group in London (UK). During his time at Jefferies he advised on several financings and M&A transactions across the biotechnology, pharmaceutical and medical devices sectors.

Bauke has a PhD in Cancer Studies from King’s College London (UK) and an MSc in Technical Medicine from the University of Twente (The Netherlands).

Nick is a Professor at the University of Warwick and co-founded NanoSyrinx with Joe and Alexia whilst supervising them both as members of his academic lab. In his academic role, Nick is particularly interested in the evolution of virulence in emerging human pathogens, and originally discovered the technology at the heart of NanoSyrinx. He retains his academic position at Warwick and advises the company as part of the Scientific Advisory Board and his position as a founding shareholder.

Nick holds a PhD from Gonville and Caius College, Cambridge in Molecular Bacteriology, and was previously a Lecturer at Bath University.

Andy is a seasoned professional in the biopharmaceutical industry with a career that spans over 25 years. As current CSO at Fujifilm Diosynth, one of the largest global contract development and manufacturing organisations, Andy brings a wealth of experience in CMC and biologic development through to GMP for clinical assets.

He received his Ph.D. from the University of Wales at Cardiff.

Pete has a long history of working in biotech and pharma, and most recently ran the UK operations for Vertex Pharma. In that role he had line management of the Biology Division – responsible for Protein Biochemistry, Crystallography/Structural Biology, Cell Biology, Enzymology and Pharmacology Leadership and development of their UK Research Portfolio from target identification through to nomination of clinical candidate. His focus was mainly oncology and neurodegenerative disease (previous areas have included sepsis and Multiple Sclerosis). Prior to Vertex Pete was at Xenova Group plc for 13 years, latterly as the Head of Biology, and before that he was a Senior Research Leader at GlaxoSmithKline for 8 years.

Pete Charlton has a DPhil in Chemistry and Enzymology from the University of Sussex.